Valuation: Alembic Pharmaceuticals Limited

Market Cap 15TCr 158.7Cr 142.44Cr 131.52Cr 119.26Cr 222.9Cr 225.64Cr 1.58TCr 626.23Cr 7.9TCr 595.72Cr 582.98Cr 25TCr P/E 2027 *
20.6x
P/E 2028 * 15.7x
Enterprise Value 16TCr 169.99Cr 152.57Cr 140.87Cr 127.75Cr 238.76Cr 241.69Cr 1.69TCr 670.77Cr 8.46TCr 638.1Cr 624.45Cr 27TCr EV / Sales 2027 *
1.91x
EV / Sales 2028 * 1.71x
Free-Float
29.3%
Yield 2027 *
1.65%
Yield 2028 * 1.99%
17/10 Alembic Pharmaceuticals Limited Receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1% CI
20/08 Alembic Pharmaceuticals Limited Announces Appointment of Chirag Shukla to Company Secretary & Compliance Officer, Effective August 20, 2026 CI
10/08 Alembic Pharmaceuticals Limited Announces Resignation of Manisha Saraf as Company Secretary and Compliance Officer, Effective August 10, 2026 CI
06/08 Alembic Pharmaceuticals Limited Appoints Mr. Sujit Jaysukh Bhayani as an Independent Director CI
04/08 Alembic Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 04, 2026
04/08 Alembic Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
04/08 India's Alembic Pharma posts quarterly profit rise on strong generics demand RE
28/07 Alembic Pharmaceuticals Limited Receives USFDA Final Approval For Prucalopride Tablets, 1 Mg And 2 Mg CI
22/07 Alembic Pharmaceuticals Receives Warning Letter From Center for Drug Evaluation and Research CI
18/07 Alembic Pharmaceuticals Limited?s Partner Natco Pharma Limited Receives USFDA Tentative Approval For Olaparib Tablets, 100 Mg and 150 Mg CI
15/07 Alembic Therapeutics LLC Announces Exclusive U.S. Distribution Of NUVESSA (Metronidazole Vaginal Gel 1.3%) CI
11/07 Alembic Pharmaceuticals Limited announces Annual dividend, payable on September 04, 2026 CI
26/06 Alembic Pharmaceuticals Limited Receives USFDA Final Approval For Oseltamivir Phosphate For Oral Suspension, 6 Mg/Ml CI
1 day+2.17%
1 week-0.56%
Current month-5.08%
1 month-8.29%
3 months-4.31%
6 months+3.18%
Current year-7.40%
1 week 748.25
Extreme 748.25
786.95
1 month 748.25
Extreme 748.25
876.4
Current year 635.8
Extreme 635.8
876.4
1 year 635.8
Extreme 635.8
998
3 years 635.8
Extreme 635.8
1,303.9
5 years 462.3
Extreme 462.3
1,303.9
10 years 414.4
Extreme 414.4
1,303.9
Manager TitleAgeSince
Director of Finance/CFO - 07/07/2025
Compliance Officer - 20/08/2026
Chief Operating Officer - 21/07/2025
Director TitleAgeSince
Chairman 78 08/06/2012
Director/Board Member 51 01/01/2007
Director/Board Member 66 18/01/2003
Date Insider Type Main position Quantity % Market Cap. Importance
28/03/25
Nirayu Pvt Ltd.
BuyCompany 12,665 0.0064%
24/03/25
Nirayu Pvt Ltd.
BuyCompany 7,600 0.0039%
21/03/25 Buy 2,000 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
+2.17%-0.56%-13.48%+6.66% 158.7Cr
+0.22%-0.14%+55.12%+128.82% 1,14300Cr
+0.91%+3.61%+41.21%+84.57% 65TCr
-0.12%-0.93%+25.59%+106.14% 51TCr
-0.46%+1.61%+52.55%+65.06% 38TCr
+0.86%-4.37%+61.16%+37.93% 35TCr
+1.34%+3.03%+32.21%+54.46% 29TCr
-0.09%+1.81%+3.51%+25.68% 26TCr
+0.75%+2.05%+53.85%+71.25% 24TCr
+0.25%+1.64%+32.05%+107.62% 20TCr
Average +0.58%+0.46%+34.38%+68.82% 40.29TCr
Weighted average by Cap. +0.37%+0.71%+43.17%+88.15%

Financials

2027 *2028 *
Net sales 8.43TCr 89Cr 80Cr 74Cr 67Cr 124.7Cr 126.23Cr 882.1Cr 350.32Cr 4.42TCr 333.26Cr 326.13Cr 14TCr 9.32TCr 98Cr 88Cr 81Cr 74Cr 137.81Cr 139.51Cr 974.89Cr 387.17Cr 4.89TCr 368.31Cr 360.44Cr 15TCr
Net income 744.47Cr 7.84Cr 7.03Cr 6.5Cr 5.89Cr 11Cr 11Cr 78Cr 31Cr 390.22Cr 29Cr 29Cr 1.24TCr 970.47Cr 10Cr 9.17Cr 8.47Cr 7.68Cr 14Cr 15Cr 101.51Cr 40Cr 508.68Cr 38Cr 38Cr 1.61TCr
Net Debt 1.07TCr 11Cr 10Cr 9.35Cr 8.48Cr 16Cr 16Cr 112.16Cr 45Cr 562.02Cr 42Cr 41Cr 1.78TCr 852.97Cr 8.98Cr 8.06Cr 7.44Cr 6.75Cr 13Cr 13Cr 89Cr 35Cr 447.09Cr 34Cr 33Cr 1.42TCr
Projected Income Statement - Annual - Alembic Pharmaceuticals Limited
Logo Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing and marketing Indian Formulations, International Generics, and Active Pharmaceutical Ingredients (APIs) across the globe. It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopedic and Gynecology. Its products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It also has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its Indian Formulations.
Employees
17,244
Date Price Change Volume
28/26/28 ₹783.55 +2.17% 93,272
27/26/27 ₹766.90 +0.07% 2,03,141
26/26/26 ₹766.40 +0.83% 43,824
23/26/23 ₹760.10 -2.71% 1,20,847
22/26/22 ₹781.30 -0.84% 45,524
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Alembic Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
766.90INR
Average target price
961.80INR
Spread / Average Target
+25.41%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alembic Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. APLLTD Stock